IS7148A - Methods for producing calcium salt form statins - Google Patents

Methods for producing calcium salt form statins

Info

Publication number
IS7148A
IS7148A IS7148A IS7148A IS7148A IS 7148 A IS7148 A IS 7148A IS 7148 A IS7148 A IS 7148A IS 7148 A IS7148 A IS 7148A IS 7148 A IS7148 A IS 7148A
Authority
IS
Iceland
Prior art keywords
statins
methods
salt form
calcium salt
producing calcium
Prior art date
Application number
IS7148A
Other languages
Icelandic (is)
Inventor
Niddam-Hildesheim Valerie
Lifshitz-Liron Revital
Lidor-Hadas Rami
Original Assignee
Teva Pharmaceutical Industries Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/037,412 external-priority patent/US6528661B2/en
Application filed by Teva Pharmaceutical Industries Ltd. filed Critical Teva Pharmaceutical Industries Ltd.
Publication of IS7148A publication Critical patent/IS7148A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55—Acids; Esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
IS7148A 2001-08-16 2004-02-11 Methods for producing calcium salt form statins IS7148A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31281201P 2001-08-16 2001-08-16
US10/037,412 US6528661B2 (en) 2000-11-16 2001-10-24 Hydrolysis of [R(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1H-pyrrole-1-heptanoic acid esters with calcium hydroxide
PCT/US2002/026012 WO2003016317A1 (en) 2001-08-16 2002-08-16 Processes for preparing calcium salt forms of statins

Publications (1)

Publication Number Publication Date
IS7148A true IS7148A (en) 2004-02-11

Family

ID=26714105

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7148A IS7148A (en) 2001-08-16 2004-02-11 Methods for producing calcium salt form statins

Country Status (17)

Country Link
EP (1) EP1425287A4 (en)
JP (2) JP4188826B2 (en)
CN (1) CN100430405C (en)
AU (1) AU2002324715B2 (en)
CA (1) CA2450820C (en)
CZ (1) CZ2004337A3 (en)
HR (1) HRPK20040255B3 (en)
HU (1) HUP0500616A3 (en)
IL (2) IL160077A0 (en)
IS (1) IS7148A (en)
MX (1) MXPA04001451A (en)
NO (1) NO20041082L (en)
NZ (1) NZ529913A (en)
PL (1) PL370407A1 (en)
SK (1) SK1402004A3 (en)
TR (1) TR200302281T2 (en)
WO (1) WO2003016317A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL155890A0 (en) * 2000-11-16 2003-12-23 Teva Pharma HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
CA2412012C (en) 2001-11-20 2011-08-02 Ed. Geistlich Soehne Ag Fuer Chemische Industrie Resorbable extracellular matrix containing collagen i and collagen ii for reconstruction of cartilage
JP4308021B2 (en) 2002-03-18 2009-08-05 バイオコン・リミテッド Amorphous HMG-CoA reductase inhibitors with desirable particle size
EP1585736A2 (en) * 2002-05-21 2005-10-19 Ranbaxy Laboratories, Ltd. Process for the preparation of rosuvastatin
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
EP1592668A1 (en) * 2003-02-12 2005-11-09 Ciba SC Holding AG Crystalline forms of pitavastatin calcium
US7232920B2 (en) 2003-04-22 2007-06-19 Biocon Process for stereoselective reduction of β-ketoesters
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
EP2522656A3 (en) * 2003-07-25 2013-03-20 Redx Pharma Limited Process and Intermediate Compounds Useful in the Preparation of Statins, Particularly Atorvastatin
WO2005019170A1 (en) * 2003-08-26 2005-03-03 Biocon Limited Novel process for preparation of 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1h-indol-2-yl]-3, 5-dihydroxy-6-heptenoic acid sodium salt
EP1816126A1 (en) * 2003-08-28 2007-08-08 Teva Pharmaceutical Industries Limited Process for preparation of rosuvastatin calcium
CA2537271A1 (en) * 2003-08-28 2005-03-17 Teva Pharmaceutical Industries, Ltd. Process for preparation of rosuvastatin calcium
UY28501A1 (en) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd CHEMICAL COMPOUNDS
AU2003272080A1 (en) 2003-09-18 2005-04-06 Biocon Limited Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
EP1678148A1 (en) * 2003-10-22 2006-07-12 Ranbaxy Laboratories Limited Process for the preparation of amorphous rosuvastatin calcium
GB0324791D0 (en) * 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
TW200526596A (en) 2003-11-24 2005-08-16 Teva Pharma Crystalline ammonium salts of rosuvastatin
MY147202A (en) * 2003-11-26 2012-11-14 Novartis Ag Compositions comprising organic compounds
EP1689723B1 (en) 2003-12-02 2011-04-27 Teva Pharmaceutical Industries, Ltd. Reference standard for characterization of rosuvastatin
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
US7943786B2 (en) * 2003-12-29 2011-05-17 Ljubomir Antoncic Process for preparing amorphous (4R-cis)-6-[2-[3-phenyl-4-(phenylcarbamoyl)-2-(4-fluorophenyl)-5-(1-methylethyl)-pyrrol-1-yl]-ethyl]-2,2-dimethyl-[1,3]-dioxane-4-yl-acetic acid
CZ200486A3 (en) * 2004-01-16 2005-08-17 Zentiva, A.S. Process for preparing hemicalcium salt of (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acid
EP1737828A1 (en) * 2004-01-19 2007-01-03 Ranbaxy Laboratories Limited Amorphous magnesium salts of rosuvastatin
US7022713B2 (en) * 2004-02-19 2006-04-04 Kowa Co., Ltd. Hyperlipemia therapeutic agent
SI21745A (en) * 2004-04-09 2005-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Polymorphs of 1-pyrrol-1-heptanoic acid derivative, intermediat for preparation of atorvastatin
US7179916B2 (en) 2004-07-13 2007-02-20 Teva Pharmaceutical Industries Ltd. Process for the preparation of rosuvastatin
US7642287B2 (en) 2004-08-06 2010-01-05 Transform Pharmaceuticals, Inc. Statin pharmaceutical compositions and related methods of treatment
TWI353981B (en) 2005-02-22 2011-12-11 Teva Pharma Preparation of rosuvastatin
CZ299215B6 (en) * 2005-06-29 2008-05-21 Zentiva, A. S. Process for preparing hemi-calcium salt of rosuvastatin, i.e. (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxy-6-heptenoic acid
CA2617805A1 (en) * 2005-08-04 2007-02-15 Transform Pharmaceuticals, Inc. Novel formulations comprising fenofibrate and a statin, and related methods of treatment
EP1805148A2 (en) 2005-08-16 2007-07-11 Teva Pharmaceutical Industries Ltd. Crystalline rosuvastatin intermediate
CN100371709C (en) * 2005-12-12 2008-02-27 重庆医药工业研究院有限责任公司 A method for separating and measuring pitavastatin and its optical isomers by liquid chromatography
WO2007125547A2 (en) * 2006-05-03 2007-11-08 Manne Satyanarayana Reddy Novel process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
EP2022784A1 (en) 2007-08-08 2009-02-11 LEK Pharmaceuticals D.D. Process for the preparation of methyl ester of rosuvastatin
US8487105B2 (en) 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
US8987444B2 (en) 2010-01-18 2015-03-24 Msn Laboratories Private Limited Process for the preparation of amide intermediates and their use thereof
HUP1000299A2 (en) 2010-06-08 2012-02-28 Nanoform Cardiovascular Therapeutics Ltd Nanostructured atorvastatin, its pharmaceutically acceptable salts and pharmaceutical compositions containing them and process for their preparation
WO2012063254A1 (en) * 2010-11-12 2012-05-18 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN102875504A (en) * 2011-07-13 2013-01-16 华南理工大学 Application of 4,5,6,7-tetrahydro pravastatin and salts thereof in cardiovascular diseases
CN102302452B (en) * 2011-09-14 2012-11-21 海南美大制药有限公司 Pitavastatin calcium lipid solid preparation
CN102796036B (en) * 2012-09-12 2014-06-04 江苏阿尔法药业有限公司 Preparation method of atorvastatin calcium
CN103724278B (en) * 2013-12-12 2019-03-29 江苏阿尔法药业有限公司 The preparation method of Statins intermediate and its derivative
JP6596339B2 (en) 2014-02-06 2019-10-23 株式会社エーピーアイ コーポレーション Method for producing rosuvastatin calcium and intermediates thereof
KR20160126700A (en) 2015-04-24 2016-11-02 미래파인켐 주식회사 New Statin intermediate, the preparation of the same and the preparation of Rosuvastatin using the same
CN105111173B (en) * 2015-06-26 2017-06-23 上海应用技术学院 Statin fluorine-containing derivant and application thereof
CN105017231B (en) * 2015-06-26 2018-01-26 上海应用技术学院 Multi-substituted indole statin fluorine-containing modification and use thereof
CN107949556B (en) 2015-08-05 2021-12-07 株式会社Api Method for producing pitavastatin calcium
CN111362856B (en) * 2020-04-29 2023-08-18 福建海西新药创制股份有限公司 Method for producing atorvastatin calcium by utilizing micro-reaction device

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
JPS5817443B2 (en) * 1976-11-02 1983-04-07 三共株式会社 Hyperlipidemia therapeutic agent whose main ingredient is ML-236B metal salt
US4857547A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
SI1148049T1 (en) * 1995-07-17 2005-02-28 Warner-Lambert Company Crystalline R-(R*,R*)$-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl -1H-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
US5669156A (en) * 1996-08-28 1997-09-23 Fleetwood Systems, Inc. Can end curing system with magnetic fanning and belt conveying
NZ503982A (en) * 1997-12-12 2002-03-28 Warner Lambert Co Statin-carboxyalkylether combinations useful for treating vascular disorders and diabetes mellitus
GB9903472D0 (en) * 1999-02-17 1999-04-07 Zeneca Ltd Chemical process
JP2002538202A (en) * 1999-03-08 2002-11-12 メルク エンド カムパニー インコーポレーテッド Dihydroxy open acid of HMG-CoA reductase inhibitor and salt thereof
IL155890A0 (en) * 2000-11-16 2003-12-23 Teva Pharma HYDROLYSIS OF [R(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID ESTERS WITH CALCIUM HYDROXIDE
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
AU2007205725A1 (en) * 2000-11-30 2007-08-30 Teva Pharmaceutical Industries Ltd. Novel cyrstal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
ES2319870T3 (en) * 2000-12-27 2009-05-14 Teva Pharmaceutical Industries Limited CRYSTALLINE FORMS OF ATORVASTATIN.
AU2001284385A1 (en) * 2001-08-31 2003-03-10 Morepen Laboratories Ltd. An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)

Also Published As

Publication number Publication date
SK1402004A3 (en) 2005-01-03
AU2002324715B2 (en) 2009-03-12
MXPA04001451A (en) 2005-02-17
CN100430405C (en) 2008-11-05
IL160077A0 (en) 2004-06-20
HUP0500616A3 (en) 2011-07-28
JP2009024008A (en) 2009-02-05
CZ2004337A3 (en) 2005-01-12
IL160077A (en) 2007-10-31
NO20041082L (en) 2004-03-15
WO2003016317A1 (en) 2003-02-27
NZ529913A (en) 2005-03-24
PL370407A1 (en) 2005-05-30
CN1543468A (en) 2004-11-03
TR200302281T2 (en) 2004-09-21
JP2005500382A (en) 2005-01-06
CA2450820C (en) 2011-03-15
CA2450820A1 (en) 2003-02-27
EP1425287A4 (en) 2005-09-07
HRP20040255A2 (en) 2004-08-31
JP4188826B2 (en) 2008-12-03
EP1425287A1 (en) 2004-06-09
HUP0500616A2 (en) 2005-11-28
HRPK20040255B3 (en) 2006-02-28

Similar Documents

Publication Publication Date Title
IS7148A (en) Methods for producing calcium salt form statins
IS7728A (en) Process for the preparation of rosuvastatin calcium salt
ATE507201T1 (en) ENERGY-EFFECTIVE CARBONYLATION PROCESS
DE60205413D1 (en) production method
EP1456132A4 (en) METHOD OF FRACTIONAL DESIONIZATION
FR2821838B1 (en) METHOD FOR LIGHTENING PLASTERBOARDS
BR0214746B1 (en) Method of producing one way clutch
DK1392609T3 (en) Method for inhibiting the formation of calcium salt deposits
PL367278A1 (en) Method for inhibiting calcium salt scale
IS7312A (en) A method for determining the bioactivity of defibrotide
DE60233109D1 (en) RADIDENTIFICATOR LOCATION PROCESS
IS6716A (en) Methods for producing cilostasol
IS7981A (en) Method for producing microsystems
ITMI20021031A0 (en) PROCEDURE FOR PREPARING POLYCARBONATE-POLYOLS
DE60226093D1 (en) Urmedium-cleaning method
DE60233230D1 (en) HEIGHT IMAGE SYNTHESIS METHOD
FI20010892L (en) Method for producing xylitol
EP1384958A4 (en) PRODUCTION SYSTEM
FI20012552L (en) Method for preparing metal carbonate
ITMO20010063A0 (en) APPARATUS FOR FORMING TILE
ITMO20010199A0 (en) APPARATUS FOR FORMING TILE
NO20012603D0 (en) Underwater production system
FI20011252A0 (en) construction method
IS6928A (en) Methods for producing mirtasapine intermediates
ITMI20021432A0 (en) METHOD FOR PRODUCING CEPHALOSPORINS